Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Auderghem – page 113

1 992 clinical trials in Auderghem, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Auderghem at a glance
1 992
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 992 trials in Auderghem

Open in trial search

Study of Intrathecal Cebsulfase Alfa for Children with Late Infantile Metachromatic Leukodystrophy

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Cebsulfase Alfa
  • Sponsor:Shire Human Genetic Therapies Inc.

Neoplasm

Not recruiting

Study on the Effects of AS01B, Ipilimumab, and Nivolumab in Patients with Advanced Melanoma

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Ipilimumab
  • Sponsor:UZ Brussel

Study of iptacopan effectiveness in achieving remission in patients with active ANCA-associated vasculitis

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Iptacopan
  • Sponsor:Novartis Pharma AG

Study on Imlifidase for Highly Sensitized Patients with End-Stage Chronic Kidney Disease Awaiting Transplant

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Imlifidase
  • Sponsor:Hansa Biopharma AB

Breast cancer female

Not recruiting

Study on Chemotherapy and Hormone Therapy for Women Over 70 with ER-Positive, HER2-Negative Breast Cancer Using Cyclophosphamide and Drug Combination

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:65+ years
  • Substances:Cyclophosphamide
  • Sponsor:Unicancer

Study on Inupadenant, Carboplatin, and Pemetrexed for Adults with Metastatic Non-Small Cell Lung Cancer After Immunotherapy

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Inupadenant Hydrochloride
  • Sponsor:iTeos Belgium

Study on BI 1015550 for Improving Lung Function in Patients with Progressive Fibrosing Interstitial Lung Diseases

Investigational
Countries:BelgiumBelgium
  • Participants:65+ years
  • Substances:Nerandomilast
  • Sponsor:Boehringer Ingelheim Espana S.A.

Study on the Effects of IO102 Hydrochloride and IO103 Acetate for Patients with Head and Neck Cancer

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:IO102 hydrochloride
  • Sponsor:Cliniques Universitaires Saint-Luc

Study of Efgartigimod for Adults with Thyroid Eye Disease

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Efgartigimod Alfa
  • Sponsor:Argenx

Neoplasm

Not recruiting

Study of OMX-0407 for Patients with Previously Treated Unresectable Solid Tumors

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:OMX-0407
  • Sponsor:iOmx Therapeutics AG

Study on the Safety and Efficacy of ARGX-119 for Adults with Amyotrophic Lateral Sclerosis (ALS)

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Humanised IgG1 monoclonal antibody against muscle specific kinase
  • Sponsor:Argenx

Study on the Effects of Sparsentan and Irbesartan for Patients with Primary Focal Segmental Glomerulosclerosis (FSGS)

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Irbesartan
  • Sponsor:Travere Therapeutics Inc.

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Auderghem

What the registry says about research in the country

01 Neoplasms

In Auderghem, researchers are concentrating on lung cancer, specifically Non‑Small Cell Lung Cancer and small cell lung cancer. The two active studies compare new immune‑targeted agents such as pumitamig and obrixtamig against established therapies like pembrolizumab and standard chemotherapy, aiming to improve overall survival and disease control.

  • Comparative efficacy of novel immunotherapies
  • Evaluation of survival benefit in advanced disease
  • Biomarker‑guided patient selection (e.g., DLL3 expression)
  • Combination regimens with checkpoint inhibitors

Both trials are actively recruiting, reflecting a growing commitment in Auderghem to advance treatment options for patients with aggressive lung cancers.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.